<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="discussion" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">781381</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2021.781381</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Opinion</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Molecular Integration in Adenosine Heteroreceptor Complexes Through Allosteric and De-Phosphorylation (STEP) Mechanisms and its Role in Brain Disease</article-title>
<alt-title alt-title-type="left-running-head">Borroto-Escuela et&#x20;al.</alt-title>
<alt-title alt-title-type="right-running-head">Adenosine Heterocomplexes and STEP Interactions</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Borroto-Escuela</surname>
<given-names>Dasiel O.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/182614/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ferraro</surname>
<given-names>Luca</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/52333/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Fuxe</surname>
<given-names>Kjell</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/41927/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Neuroscience, Karolinska Institutet</institution>, <addr-line>Stockholm</addr-line>, <country>Sweden</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Life Sciences and Biotechnology, University of Ferrara</institution>, <addr-line>Ferrara</addr-line>, <country>Italy</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1402944/overview">Zhan-Guo Gao</ext-link>, National Institute of Diabetes and Digestive and Kidney Diseases (NIH), United&#x20;States</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/516654/overview">Manuel Narvaez Pel&#xe1;ez</ext-link>, University of Malaga, Spain</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1689/overview">Rafael Franco</ext-link>, University of Barcelona, Spain</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Dasiel O. Borroto-Escuela, <email>dasiel.borroto.escuela@ki.se</email>; Kjell Fuxe, <email>kjell.fuxe@ki.se</email>
</corresp>
<fn fn-type="other">
<p>This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>05</day>
<month>01</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>12</volume>
<elocation-id>781381</elocation-id>
<history>
<date date-type="received">
<day>22</day>
<month>09</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>09</day>
<month>12</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2022 Borroto-Escuela, Ferraro and Fuxe.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Borroto-Escuela, Ferraro and Fuxe</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these&#x20;terms.</p>
</license>
</permissions>
<kwd-group>
<kwd>adenosine receptors</kwd>
<kwd>adenosine heteroreceptor complexes</kwd>
<kwd>dopmaine heteroreceptor complexes, mu-opioid heteroreceptor complexes</kwd>
<kwd>G protein coupled receptors (GPCR)</kwd>
<kwd>receptor-receptor interactions</kwd>
<kwd>striatal-enriched protein tyrosine phosphatase</kwd>
<kwd>allosteric modulation</kwd>
</kwd-group>
<contract-num rid="cn001">04X-715</contract-num>
<contract-num rid="cn002">2021 2019</contract-num>
<contract-num rid="cn003">F02019-0296</contract-num>
<contract-sponsor id="cn001">Vetenskapsr&#xe5;det<named-content content-type="fundref-id">10.13039/501100004359</named-content>
</contract-sponsor>
<contract-sponsor id="cn002">Stiftelsen Olle Engkvist Byggm&#xe4;stare<named-content content-type="fundref-id">10.13039/501100004200</named-content>
</contract-sponsor>
<contract-sponsor id="cn003">Hj&#xe4;rnfonden<named-content content-type="fundref-id">10.13039/501100003792</named-content>
</contract-sponsor>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Dysfunction of adenosine heteroreceptor complexes can contribute to mental disorder development (<xref ref-type="bibr" rid="B7">Borroto-Escuela et&#x20;al., 2018a</xref>; <xref ref-type="bibr" rid="B2">Beggiato et&#x20;al., 2021</xref>; <xref ref-type="bibr" rid="B26">Merighi et&#x20;al., 2021</xref>). Furthermore, a molecular basis for learning and memory was proposed to be formed through reorganization of available adenosine homo- and heteroreceptor complexes as to structural functions and/or by resetting the multiple allosteric receptor-receptor interactions in these complexes. Based on this evidence, this Opinion article is focused on the underlying relevance of adenosine heteroreceptor complexes in the brain and their integrative mechanisms at the molecular level, involving allosteric receptor-receptor interactions and dephosphorylation mechanisms through Striatal-Enriched Protein Tyrosine Phosphatase (STEP) (<xref ref-type="bibr" rid="B17">Franco et&#x20;al., 2020b</xref>; <xref ref-type="bibr" rid="B33">Yasuda, 2020</xref>; <xref ref-type="bibr" rid="B4">Borroto-Escuela et&#x20;al., 2021a</xref>; <xref ref-type="bibr" rid="B1">Barresi et&#x20;al., 2021</xref>; <xref ref-type="bibr" rid="B8">Borroto-Escuela et&#x20;al., 2021b</xref>; <xref ref-type="bibr" rid="B2">Beggiato et&#x20;al., 2021</xref>; <xref ref-type="bibr" rid="B13">Domenici et&#x20;al., 2021</xref>).</p>
<p>This enzyme is a tyrosine phosphatase specific to the brain and its substrate is represented by a vast network of synaptic and extra synaptic proteins (<xref ref-type="bibr" rid="B23">Lombroso et&#x20;al., 1993</xref>; <xref ref-type="bibr" rid="B31">Won et&#x20;al., 2019</xref>). Several splice variants exist, namely STEP<sub>61,</sub> STEP<sub>46,</sub> STEP<sub>38</sub>, and STEP<sub>20</sub>. However, only STEP<sub>46</sub> is enriched in the striatum and STEP<sub>61</sub> shows a widespread distribution with high densities e.g., in cerebral cortex and hippocampus (<xref ref-type="bibr" rid="B32">Won and Roche, 2021</xref>). STEP has several functions through it dephosphorylation, via its enzymatic activity, of synaptic and extra synaptic proteins including kinases and glutamate receptors like NMDARs and AMPARs producing synaptic downregulation (<xref ref-type="bibr" rid="B35">Zhang et&#x20;al., 2008</xref>; <xref ref-type="bibr" rid="B31">Won et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B32">Won and Roche, 2021</xref>). STEP dysfunction may therefore lead to disturbances in synaptic plasticity necessary for cognition. How STEP and adenosine A2A heteroreceptor complexes can modulate between each other and have a role in molecular integration of adenosine signal in the brain, is the focus of this opinion article.</p>
</sec>
<sec id="s2">
<title>Understanding the Mechanisms for A2AR Mediated Activation of STEP: Involvement of A2AR Heterocomplexes</title>
<p>Robert Yasuda (<xref ref-type="bibr" rid="B33">Yasuda, 2020</xref>) wrote a highly interesting Editorial on STEP (Striatal -enriched protein tyrosine phosphatase in neuronal cells and its modulation by adenosine A2A receptors (<xref ref-type="bibr" rid="B25">Mallozzi et&#x20;al., 2020</xref>), published in Journal of Neurochemistry. As discussed by <xref ref-type="bibr" rid="B33">Yasuda (2020)</xref>, cocaine induced increases in brain adenosine levels (<xref ref-type="bibr" rid="B21">Kubrusly and Bhide, 2010</xref>) can help explain how cocaine can activate the A2AR which leads to increases in the dephosphorylation activity of STEP on synaptic glutamate receptors with associated depression of synaptic activity (<xref ref-type="bibr" rid="B25">Mallozzi et&#x20;al., 2020</xref>). These results are supported by the early work on cocaine by <xref ref-type="bibr" rid="B11">Chiodi et&#x20;al. (2014)</xref>. Also by the observation that A2AR mediated synaptic depression was counteracted not only by an A2AR antagonist but also by a dopamine D2R antagonist. This can be explained by the fact these two receptors are primarily located in the dorsal and ventral striatal pallidal GABA neurons mediating motor inhibition and antireward, respectively (<xref ref-type="bibr" rid="B4">Borroto-Escuela et&#x20;al., 2021a</xref>; <xref ref-type="bibr" rid="B8">Borroto-Escuela et&#x20;al., 2021b</xref>).</p>
<p>The D2R activation markedly inhibits the firing of these two types of neurons via its inhibitory Gi/o coupling of the D2R, causing increases in motor activity and reductions of anti-reward. The striatal-pallidal GABA neurons are enriched in A2AR-D2R heterocomplexes in which the activated A2AR protomer strongly blocks the D2R protomer mediated signaling through allosteric inhibition of the D2R protomer (<xref ref-type="bibr" rid="B8">Borroto-Escuela et&#x20;al., 2021b</xref>) (<xref ref-type="fig" rid="F1">Figure&#x20;1</xref>). It should be noted that the work of the Italian group in 2020 takes place in striatum, which may be further defined as to the possible inclusion also of the ventral striatum or if it only involved the dorsal striatum. Robert Yasuda indicates the relevance of these antagonistic A2AR-D2R interactions in the A2AR-D2R heterocomplexes of the ventral striatal-pallidal GABA neurons for the A2AR mediated inhibition of cocaine self-administration (<xref ref-type="bibr" rid="B4">Borroto-Escuela et&#x20;al., 2021a</xref>; <xref ref-type="bibr" rid="B8">Borroto-Escuela et&#x20;al., 2021b</xref>). Disruption of this receptor complex with an interface interfering peptide in fact blocks the A2AR mediated inhibition of cocaine self-administration (<xref ref-type="bibr" rid="B9">Borroto-Escuela et&#x20;al., 2018b</xref>). This A2AR-D2R mechanism lacks the pathway to induce STEP activation.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Illustration of allosteric receptor-receptor interactions is shown in D2R-A2AR, A2AR-mGluR5 and A2BR-A2AR heterocomplexes and of activation of STEP through enhanced mGluR5 protomer signaling. To the left side, the A2AR agonist activation of the A2AR protomer leads to allosteric inhibition of the inhibitory Gi/o mediated signaling of the D2R, reducing the inhibition of the adenylate cyclase (AC). To the right side the constitutive activity (black line) of the A2BR leads to an allosteric downregulation of the Gs mediated activation of the A2AR. In the center the facilitatory allosteric interactions in the A2AR-mGluR5 heterocomplex is illustrated. It involves enhanced activity of the Gq mediated signaling of the mGluR5 with enhanced PLC-beta signaling leading to increased PKC activity with the enhanced formation IP3 increasing intracellular calcium levels. As a result, the calcineurin-PP1 pathway becomes activated and dephosphorylates STEP which causes its activation. The activated STEP can then dephosphorylate NMDAR and AMPAR with a return of the hydroxyl (OH) groups and a synaptic down regulation takes place. Also, mGluR5 binds STEP and becomes inactivated through its de-phosphorylation. In this way the mGluR5 may no longer be activated which becomes true also for Calcineurin and STEP activity becomes reduced with the return of synaptic activity.</p>
</caption>
<graphic xlink:href="fphar-12-781381-g001.tif"/>
</fig>
<p>The first indication that cocaine self-administration increases the enzymatic activity of STEP was obtained in the prefrontal cortex in 2013 (<xref ref-type="bibr" rid="B29">Sun et&#x20;al., 2013</xref>), leading to diminished expression of GluN. The following year it was found that cocaine in micromolar concentrations diminished excitatory post-synaptic transmission in the dorsal striatum that involved STEP activation (<xref ref-type="bibr" rid="B11">Chiodi et&#x20;al., 2014</xref>). It was pointed out that the blockade of the synaptic depression by an A2AR antagonist, indicated the participation of A2ARs (<xref ref-type="bibr" rid="B33">Yasuda, 2020</xref>). These results were additionally supported by the observations that A2AR overexpression in the brain, especially in striatum, could produce increased STEP activity (<xref ref-type="bibr" rid="B25">Mallozzi et&#x20;al., 2020</xref>). Yasuda in his editorial (<xref ref-type="bibr" rid="B33">Yasuda, 2020</xref>) searched for a possible mechanism by which A2AR activation could increase STEP activity. He discussed in a clear way how STEP could be activated in the striatal-pallidal GABA pathway by increased A2AR functionality, capable of producing increases in intracellular calcium levels. It involved activation of phospholipase C (PLC) followed by IP3 induced increases in intracellular calcium levels leading to calcineurin/PP1 activation causing dephosphorylation of STEP which induces its activation (<xref ref-type="bibr" rid="B33">Yasuda, 2020</xref>; <xref ref-type="bibr" rid="B13">Domenici et&#x20;al., 2021</xref>).</p>
</sec>
<sec id="s3">
<title>Understanding the Role of the A2AR-mGluR5 Heterocomplexes in STEP Activation</title>
<p>In the striatal-pallidal GABA neurons, in which A2AR-D2R heterocomplexes are enriched (<xref ref-type="bibr" rid="B4">Borroto-Escuela et&#x20;al., 2021a</xref>) there also exist A2AR-mGluR5 and A2AR-mGluR5-D2R heterocomplexes (<xref ref-type="bibr" rid="B14">Ferre et&#x20;al., 2002</xref>; <xref ref-type="bibr" rid="B12">Ciruela et&#x20;al., 2005</xref>; <xref ref-type="bibr" rid="B18">Fuxe et&#x20;al., 2008</xref>; <xref ref-type="bibr" rid="B10">Cabello et&#x20;al., 2009</xref>; <xref ref-type="bibr" rid="B6">Borroto-Escuela et&#x20;al., 2017</xref>). It is known that A2AR may allosterically enhance the mGluR5 signaling and its Gq/11 mediated signaling coupled to activation of PLC leading to increases in calcium levels and activation of calcineurin and activation of STEP as discussed (<xref ref-type="bibr" rid="B33">Yasuda, 2020</xref>; <xref ref-type="bibr" rid="B4">Borroto-Escuela et&#x20;al., 2021a</xref>; <xref ref-type="bibr" rid="B13">Domenici et&#x20;al., 2021</xref>).</p>
<p>It is also of high interest that STEP can bind to mGluR5, showing a special role of mGluR5 capable not only to activate STEP but also by its own ability to bind and be downregulated by this phosphatase (<xref ref-type="bibr" rid="B31">Won et&#x20;al., 2019</xref>) (<xref ref-type="fig" rid="F1">Figure&#x20;1</xref>). Furthermore, STEP can produce downregulation of AMPA receptors upon mGluR1/5 receptor activation (<xref ref-type="bibr" rid="B35">Zhang et&#x20;al., 2008</xref>).</p>
<p>Yasuda (<xref ref-type="bibr" rid="B33">Yasuda, 2020</xref>) also discussed theA2AR overexpression model used in the Mallozzi et&#x20;al. (<xref ref-type="bibr" rid="B25">Mallozzi et&#x20;al., 2020</xref>) paper to establish the strong activation of A2AR leading to increased STEP activity in striatum and hippocampus counteracted by an A2AR antagonist which failed to have effects in wild-type animals. It seems possible that upon A2AR overexpression a marked increase in the density of the A2AR-mGluR5 complexes can develop. These events can contribute to the strong activation of STEP leading to the downregulation of excitatory synaptic signaling with substantial negative consequences for learning and memory (<xref ref-type="bibr" rid="B19">Gimenez-Llort et&#x20;al., 2007</xref>; <xref ref-type="bibr" rid="B3">Borroto-Escuela et&#x20;al., 2015</xref>; <xref ref-type="bibr" rid="B20">Hamor et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B33">Yasuda, 2020</xref>).</p>
</sec>
<sec id="s4">
<title>The Balance of A2AR-mGluR5 and A2AR-D2R Heterocomplexes in Cocaine Self-Administration</title>
<p>Substantial differences were observed in ventral compared to dorsal striatum regarding the results obtained in effects of cocaine self-administration on A2AR-mGluR5 and A2AR-D2R heterocomplexes (<xref ref-type="bibr" rid="B6">Borroto-Escuela et&#x20;al., 2017</xref>). In contrast to the dorsal striatum, there was a clear-cut and significant increase of the A2AR-D2R heterocomplexes and a trend for an increase for the A2AR-mGluR5 heterocomplexes in nucleus accumbens shell (<xref ref-type="bibr" rid="B6">Borroto-Escuela et&#x20;al., 2017</xref>). These results are compatible with a preferential allosteric enhancement by the A2AR agonist of the mGluR5 protomer signaling in this complex located in the nucleus accumbens shell versus the dorsal striatum. It should lead to increased activation of STEP as discussed, associated with an excitatory synaptic downregulation. In parallel, the A2AR agonist will strongly inhibit the D2R protomer signaling in this region of the nucleus accumbens. The significance of these two allosteric events induced by the A2AR agonist leading to inhibition of the D2R protomer and to synaptic downregulation of parts of the ventral striatal-pallidal GABA antireward neurons remains to be determined. However, differences in their time dynamics can play a role with the A2AR mediated inhibition of the D2R signaling being more long-lasting versus more dynamic changes in the excitatory synaptic transmission.</p>
<p>The absence of increases in A2AR-mGluR5 heterocomplexes in the caudate putamen in cocaine self-administration opened the existence for another A2AR mechanism mediating the activation of STEP. It was proposed that the A2AR-FGFR1 heterocomplex discovered in the dorsal striatum (<xref ref-type="bibr" rid="B15">Flajolet et&#x20;al., 2008</xref>) could be involved in mediating the STEP activation (<xref ref-type="bibr" rid="B4">Borroto-Escuela et&#x20;al., 2021a</xref>). It was suggested that a new panorama of transcriptional proteins could be formed upon co-activation of this receptor complex leading to formation of proteins with phosphatase activity taking over the function of e.g., protein-tyrosine-phosphatase 1 (PPT1) (<xref ref-type="bibr" rid="B4">Borroto-Escuela et&#x20;al., 2021a</xref>).</p>
</sec>
<sec id="s5">
<title>Understanding the Role of A2AR Heterocomplexes in STEP Actions in Alzheimer&#x2019;s Disease and Parkinson&#x2019;s Disease</title>
<p>It is known that STEP is elevated in Alzheimer&#x2019;s disease and produces significant increases in synaptic down-regulation through dephosphorylation and internalization of e.g., N-methyl-d-aspartate receptor (NMDAR) and &#x3b1;-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) (<xref ref-type="bibr" rid="B28">Snyder et&#x20;al., 2005</xref>; <xref ref-type="bibr" rid="B35">Zhang et&#x20;al., 2008</xref>; <xref ref-type="bibr" rid="B34">Zhang et&#x20;al., 2010</xref>). It is of special interest that long-term activation of the NMDAR through stimulation of the calcineurin/PP1 intracellular pathway can dephosphorylate STEP leading to its activation in the striatum (<xref ref-type="bibr" rid="B30">Valjent et&#x20;al., 2005</xref>). It can represent a significant feed-back to counteract an overactivation of the NMDAR which can lead to excitotoxicity (<xref ref-type="bibr" rid="B24">Mahaman et&#x20;al., 2021</xref>).</p>
<p>Recently it was proposed the existence of putative A2AR-D2R-NMDAR heterocomplexes (<xref ref-type="bibr" rid="B5">Borroto-Escuela and Fuxe, 2019</xref>). It should be underlined that D2R can also form complexes with the NMDAR in which allosteric inhibitory D2R-NMDAR receptor subtype 2B (NR2B) interactions exist (<xref ref-type="bibr" rid="B22">Liu et&#x20;al., 2006</xref>). It was also possible to demonstrate with BRET and <italic>in situ</italic> PLA the existence of NMDAR-A2AR heteroreceptor complex in HEK and microglia cells (<xref ref-type="bibr" rid="B16">Franco et&#x20;al., 2020a</xref>). The results from <xref ref-type="bibr" rid="B16">Franco et&#x20;al. (2020a)</xref> may indicate that the A2AR expression can increase the function of the NMDAR signaling in microglial cells, while the activation of the NMDAR can block the A2AR function. Furthermore, antagonistic allosteric receptor-receptor interactions may exist within the A2AR-NMDAR heteromer. Based on these findings it was proposed that A2AR antagonists have a potential to counteract neurodegeneration in Alzheimer&#x2019;s disease.</p>
<p>In the paper of Borroto-Escuela and Fuxe (<xref ref-type="bibr" rid="B5">Borroto-Escuela and Fuxe, 2019</xref>), it was suggested that the alpha-synuclein monomer (alpha conformation) may bind to the A2AR protomer of the A2AR-D2R-NMDAR heterocomplex. The alpha-synuclein monomer may enhance the A2AR protomer activation and thus its allosteric inhibition of the D2R protomer signaling. As a consequence, the allosteric inhibition by the D2R protomer of the NMDAR protomer is reduced (<xref ref-type="bibr" rid="B22">Liu et&#x20;al., 2006</xref>) and NMDAR function can become strongly enhanced with increased calcium influx over its ion channels.</p>
<p>This leads to coupling to nitric oxide production and toxicity. The calcium influx can then via the calcineurine/PP1 pathway de-phosphorylate STEP leading to its activation. In this way the STEP can bring down NMDAR signaling and induce its internalization and block the excitotoxicity caused by excessive activation of the NMDAR. These results give increased implications for using A2AR antagonists in the treatment of Parkinson&#x2019;s disease (<xref ref-type="bibr" rid="B5">Borroto-Escuela and Fuxe, 2019</xref>; <xref ref-type="bibr" rid="B27">Perez de la Mora et&#x20;al., 2020</xref>). Finally, it should be considered that beta sheet intermediates of alpha-synuclein peptides may bind to the intracellular loops and C terminals of the GPCR protomers of the heteroreceptor trimeric complex and modulate its signaling and its response to activated&#x20;STEP.</p>
</sec>
</body>
<back>
<sec id="s6">
<title>Author Contributions</title>
<p>All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.</p>
</sec>
<sec id="s7">
<title>Funding</title>
<p>This work was supported by grants from Stiftelsen Olle Engkvist Byggm&#xe4;stare, Stockholm, Swedish Medical Research Council (Vetenskapsr&#xe5;det; 04X-715) to KF and from Hj&#xe4;rnfonden (F02018-0286), Hj&#xe4;rnfonden (F02019-0296), Karolinska Institutet Forskningsstiftelser and EMERGIA 2020-39318 (Plan Andaluz de Investigaci&#xf3;n, Desarrollo e Innovaci&#xf3;n 2020) to DB-E. DB-E belong to Academia de Bi&#xf3;logos Cubanos.</p>
</sec>
<sec sec-type="COI-statement" id="s8">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
<p>The reviewer RF declared a past co-authorship with authors KF and DOBE to the handling editor.</p>
</sec>
<sec sec-type="disclaimer" id="s9">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barresi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Martini</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Da Settimo</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Greco</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Taliani</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Giacomelli</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Allosterism vs. Orthosterism: Recent Findings and Future Perspectives on A2B AR Physio-Pathological Implications</article-title>. <source>Front. Pharmacol.</source> <volume>12</volume>, <fpage>652121</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2021.652121</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beggiato</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zuccarini</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cassano</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Borroto-Escuela</surname>
<given-names>D. O.</given-names>
</name>
<name>
<surname>Di Iorio</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Schwarcz</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Adenosine and Kynurenic Acid Interactions: Possible Relevance for Schizophrenia Treatment?</article-title> <source>Front. Pharmacol.</source> <volume>12</volume>, <fpage>654426</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2021.654426</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borroto-Escuela</surname>
<given-names>D. O.</given-names>
</name>
<name>
<surname>Agnati</surname>
<given-names>L. F.</given-names>
</name>
<name>
<surname>Bechter</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Jansson</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tarakanov</surname>
<given-names>A. O.</given-names>
</name>
<name>
<surname>Fuxe</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>The Role of Transmitter Diffusion and Flow versus Extracellular Vesicles in Volume Transmission in the Brain Neural-Glial Networks</article-title>. <source>Philos. Trans. R. Soc. Lond. B Biol. Sci.</source> <volume>370</volume> (<issue>1672</issue>), <fpage>20140183</fpage>. <pub-id pub-id-type="doi">10.1098/rstb.2014.0183</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borroto-Escuela</surname>
<given-names>D. O.</given-names>
</name>
<name>
<surname>Ferraro</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Beggiato</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Narv&#xe1;ez</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fores-Pons</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Alvarez-Contino</surname>
<given-names>J.&#x20;E.</given-names>
</name>
<etal/>
</person-group> (<year>2021a</year>). <article-title>The Coming Together of Allosteric and Phosphorylation Mechanisms in the Molecular Integration of A2A Heteroreceptor Complexes in the Dorsal and Ventral Striatal-Pallidal GABA Neurons</article-title>. <source>Pharmacol. Rep.</source> <volume>73</volume> (<issue>4</issue>), <fpage>1096</fpage>&#x2013;<lpage>1108</lpage>. <pub-id pub-id-type="doi">10.1007/s43440-021-00314-3</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borroto-Escuela</surname>
<given-names>D. O.</given-names>
</name>
<name>
<surname>Fuxe</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Adenosine Heteroreceptor Complexes in the Basal Ganglia Are Implicated in Parkinson&#x27;s Disease and its Treatment</article-title>. <source>J.&#x20;Neural Transm. (Vienna)</source> <volume>126</volume> (<issue>4</issue>), <fpage>455</fpage>&#x2013;<lpage>471</lpage>. <pub-id pub-id-type="doi">10.1007/s00702-019-01969-2</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borroto-Escuela</surname>
<given-names>D. O.</given-names>
</name>
<name>
<surname>Narv&#xe1;ez</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wydra</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Pintsuk</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pinton</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jimenez-Beristain</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Cocaine Self-Administration Specifically Increases A2AR-D2R and D2R-sigma1R Heteroreceptor Complexes in the Rat Nucleus Accumbens Shell. Relevance for Cocaine Use Disorder</article-title>. <source>Pharmacol. Biochem. Behav.</source> <volume>155</volume>, <fpage>24</fpage>&#x2013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/j.pbb.2017.03.003</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borroto-Escuela</surname>
<given-names>D. O.</given-names>
</name>
<name>
<surname>Wydra</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Filip</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fuxe</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2018a</year>). <article-title>A2AR-D2R Heteroreceptor Complexes in Cocaine Reward and Addiction</article-title>. <source>Trends Pharmacol. Sci.</source> <volume>39</volume> (<issue>12</issue>), <fpage>1008</fpage>&#x2013;<lpage>1020</lpage>. <pub-id pub-id-type="doi">10.1016/j.tips.2018.10.007</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borroto-Escuela</surname>
<given-names>D. O.</given-names>
</name>
<name>
<surname>Wydra</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Fores-Pons</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Vasudevan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Romero-Fernandez</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Frankowska</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2021b</year>). <article-title>The Balance of MU-Opioid, Dopamine D2 and Adenosine A2A Heteroreceptor Complexes in the Ventral Striatal-Pallidal GABA Antireward Neurons May Have a Significant Role in Morphine and Cocaine Use Disorders</article-title>. <source>Front. Pharmacol.</source> <volume>12</volume>, <fpage>627032</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2021.627032</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borroto-Escuela</surname>
<given-names>D. O.</given-names>
</name>
<name>
<surname>Wydra</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Rodriguez</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Carlsson</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jastrz&#x119;bska</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2018b</year>). <article-title>Disruption of A2AR-D2R Heteroreceptor Complexes after A2AR Transmembrane 5 Peptide Administration Enhances Cocaine Self-Administration in Rats</article-title>. <source>Mol. Neurobiol.</source> <volume>55</volume> (<issue>8</issue>), <fpage>7038</fpage>&#x2013;<lpage>7048</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-018-0887-1</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cabello</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Gand&#xed;a</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bertarelli</surname>
<given-names>D. C.</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Llu&#xed;s</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Franco</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2009</year>). <article-title>Metabotropic Glutamate Type 5, Dopamine D2 and Adenosine A2a Receptors Form Higher-Order Oligomers in Living Cells</article-title>. <source>J.&#x20;Neurochem.</source> <volume>109</volume> (<issue>5</issue>), <fpage>1497</fpage>&#x2013;<lpage>1507</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2009.06078.x</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chiodi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Mallozzi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ferrante</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.&#x20;F.</given-names>
</name>
<name>
<surname>Lombroso</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Di Stasi</surname>
<given-names>A. M.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Cocaine-induced Changes of Synaptic Transmission in the Striatum Are Modulated by Adenosine A2A Receptors and Involve the Tyrosine Phosphatase STEP</article-title>. <source>Neuropsychopharmacology</source> <volume>39</volume> (<issue>3</issue>), <fpage>569</fpage>&#x2013;<lpage>578</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2013.229</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ciruela</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Canela</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Burgue&#xf1;o</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Soriguera</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cabello</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Canela</surname>
<given-names>E. I.</given-names>
</name>
<etal/>
</person-group> (<year>2005</year>). <article-title>Heptaspanning Membrane Receptors and Cytoskeletal/scaffolding Proteins: Focus on Adenosine, Dopamine, and Metabotropic Glutamate Receptor Function</article-title>. <source>J.&#x20;Mol. Neurosci.</source> <volume>26</volume> (<issue>2-3</issue>), <fpage>277</fpage>&#x2013;<lpage>292</lpage>. <pub-id pub-id-type="doi">10.1385/JMN:26:2-3:277</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Domenici</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Mallozzi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pepponi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Casella</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Chiodi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Ferrante</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Insight into the Role of the STriatal-Enriched Protein Tyrosine Phosphatase (STEP) in A2A Receptor-Mediated Effects in the Central Nervous System</article-title>. <source>Front. Pharmacol.</source> <volume>12</volume>, <fpage>647742</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2021.647742</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferr&#xe9;</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Karcz-Kubicha</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hope</surname>
<given-names>B. T.</given-names>
</name>
<name>
<surname>Popoli</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Burgue&#xf1;o</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Guti&#xe9;rrez</surname>
<given-names>M. A.</given-names>
</name>
<etal/>
</person-group> (<year>2002</year>). <article-title>Synergistic Interaction between Adenosine A2A and Glutamate mGlu5 Receptors: Implications for Striatal Neuronal Function</article-title>. <source>Proc. Natl. Acad. Sci. U S A.</source> <volume>99</volume> (<issue>18</issue>), <fpage>11940</fpage>&#x2013;<lpage>11945</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.172393799</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Flajolet</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Futter</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Nuangchamnong</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Bendor</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2008</year>). <article-title>FGF Acts as a Co-transmitter through Adenosine A(2A) Receptor to Regulate Synaptic Plasticity</article-title>. <source>Nat. Neurosci.</source> <volume>11</volume> (<issue>12</issue>), <fpage>1402</fpage>&#x2013;<lpage>1409</lpage>. <pub-id pub-id-type="doi">10.1038/nn.2216</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Franco</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Rivas-Santisteban</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Casanovas</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lillo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Saura</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Navarro</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2020a</year>). <article-title>Adenosine A2A Receptor Antagonists Affects NMDA Glutamate Receptor Function. Potential to Address Neurodegeneration in Alzheimer&#x27;s DiseasePotential to Address Neurodegeneration in Alzheimer&#x27;s Disease</article-title>. <source>Cells</source> <volume>9</volume> (<issue>5</issue>), <fpage>1075</fpage>. <pub-id pub-id-type="doi">10.3390/cells9051075</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Franco</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Rivas-Santisteban</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Reyes-Resina</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Navarro</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2020b</year>). <article-title>The Old and New Visions of Biased Agonism through the Prism of Adenosine Receptor Signaling and Receptor/Receptor and Receptor/Protein Interactions</article-title>. <source>Front. Pharmacol.</source> <volume>11</volume>, <fpage>628601</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2020.628601</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fuxe</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Marcellino</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rivera</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Diaz-Cabiale</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Filip</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gago</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2008</year>). <article-title>Receptor-receptor Interactions within Receptor Mosaics. Impact on Neuropsychopharmacology</article-title>. <source>Brain Res. Rev.</source> <volume>58</volume> (<issue>2</issue>), <fpage>415</fpage>&#x2013;<lpage>452</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainresrev.2007.11.007</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gim&#xe9;nez-Llort</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Schiffmann</surname>
<given-names>S. N.</given-names>
</name>
<name>
<surname>Shmidt</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Canela</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Cam&#xf3;n</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wassholm</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2007</year>). <article-title>Working Memory Deficits in Transgenic Rats Overexpressing Human Adenosine A2A Receptors in the Brain</article-title>. <source>Neurobiol. Learn. Mem.</source> <volume>87</volume> (<issue>1</issue>), <fpage>42</fpage>&#x2013;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1016/j.nlm.2006.05.004</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>H&#xe1;mor</surname>
<given-names>P. U.</given-names>
</name>
<name>
<surname>Gobin</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Schwendt</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>The Role of Glutamate mGlu5 and Adenosine A2a Receptor Interactions in Regulating Working Memory Performance and Persistent Cocaine Seeking in Rats</article-title>. <source>Prog. Neuropsychopharmacol. Biol. Psychiatry</source> <volume>103</volume>, <fpage>109979</fpage>. <pub-id pub-id-type="doi">10.1016/j.pnpbp.2020.109979</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kubrusly</surname>
<given-names>R. C.</given-names>
</name>
<name>
<surname>Bhide</surname>
<given-names>P. G.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Cocaine Exposure Modulates Dopamine and Adenosine Signaling in the Fetal Brain</article-title>. <source>Neuropharmacology</source> <volume>58</volume> (<issue>2</issue>), <fpage>436</fpage>&#x2013;<lpage>443</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2009.09.007</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>X. Y.</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>X. P.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>L. M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lan</surname>
<given-names>H. X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M. H.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>Modulation of D2R-Nr2b Interactions in Response to Cocaine</article-title>. <source>Neuron</source> <volume>52</volume> (<issue>5</issue>), <fpage>897</fpage>&#x2013;<lpage>909</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2006.10.011</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lombroso</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Naegele</surname>
<given-names>J.&#x20;R.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Lerner</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>1993</year>). <article-title>A Protein Tyrosine Phosphatase Expressed within Dopaminoceptive Neurons of the Basal Ganglia and Related Structures</article-title>. <source>J.&#x20;Neurosci.</source> <volume>13</volume> (<issue>7</issue>), <fpage>3064</fpage>&#x2013;<lpage>3074</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.13-07-03064.1993</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mahaman</surname>
<given-names>Y. A. R.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Embaye</surname>
<given-names>K. S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>The Implication of STEP in Synaptic Plasticity and Cognitive Impairments in Alzheimer&#x27;s Disease and Other Neurological Disorders</article-title>. <source>Front Cel Dev Biol.</source> <volume>9</volume>, <fpage>680118</fpage>. <pub-id pub-id-type="doi">10.3389/fcell.2021.680118</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mallozzi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pepponi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Visentin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chiodi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Lombroso</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Bader</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>The Activity of the Striatal-Enriched Protein Tyrosine Phosphatase in Neuronal Cells Is Modulated by Adenosine A2A Receptor</article-title>. <source>J.&#x20;Neurochem.</source> <volume>152</volume> (<issue>3</issue>), <fpage>284</fpage>&#x2013;<lpage>298</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.14866</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Merighi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Poloni</surname>
<given-names>T. E.</given-names>
</name>
<name>
<surname>Pelloni</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pasquini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Varani</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Vincenzi</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>An Open Question: Is the A2A Adenosine Receptor a Novel Target for Alzheimer&#x27;s Disease Treatment?</article-title> <source>Front. Pharmacol.</source> <volume>12</volume>, <fpage>652455</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2021.652455</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perez de la Mora</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hernandez-Mondragon</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Crespo-Ramirez</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rejon-Orantes</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Borroto-Escuela</surname>
<given-names>D. O.</given-names>
</name>
<name>
<surname>Fuxe</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Conventional and Novel Pharmacological Approaches to Treat Dopamine-Related Disorders: Focus on Parkinson&#x27;s Disease and Schizophrenia</article-title>. <source>Neuroscience</source> <volume>439</volume>, <fpage>301</fpage>&#x2013;<lpage>318</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2019.07.026</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Snyder</surname>
<given-names>E. M.</given-names>
</name>
<name>
<surname>Nong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Almeida</surname>
<given-names>C. G.</given-names>
</name>
<name>
<surname>Paul</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Moran</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>E. Y.</given-names>
</name>
<etal/>
</person-group> (<year>2005</year>). <article-title>Regulation of NMDA Receptor Trafficking by Amyloid-Beta</article-title>. <source>Nat. Neurosci.</source> <volume>8</volume> (<issue>8</issue>), <fpage>1051</fpage>&#x2013;<lpage>1058</lpage>. <pub-id pub-id-type="doi">10.1038/nn1503</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>W. L.</given-names>
</name>
<name>
<surname>Zelek-Molik</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>McGinty</surname>
<given-names>J.&#x20;F.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Short and Long Access to Cocaine Self-Administration Activates Tyrosine Phosphatase STEP and Attenuates GluN Expression but Differentially Regulates GluA Expression in the Prefrontal Cortex</article-title>. <source>Psychopharmacology (Berl)</source> <volume>229</volume> (<issue>4</issue>), <fpage>603</fpage>&#x2013;<lpage>613</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-013-3118-5</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valjent</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Pascoli</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Svenningsson</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Paul</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Enslen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Corvol</surname>
<given-names>J.&#x20;C.</given-names>
</name>
<etal/>
</person-group> (<year>2005</year>). <article-title>Regulation of a Protein Phosphatase cascade Allows Convergent Dopamine and Glutamate Signals to Activate ERK in the Striatum</article-title>. <source>Proc. Natl. Acad. Sci. U S A.</source> <volume>102</volume> (<issue>2</issue>), <fpage>491</fpage>&#x2013;<lpage>496</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0408305102</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Won</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Incontro</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nicoll</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Roche</surname>
<given-names>K. W.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>The STEP61 Interactome Reveals Subunit-specific AMPA Receptor Binding and Synaptic Regulation</article-title>. <source>Proc. Natl. Acad. Sci. U S A.</source> <volume>116</volume> (<issue>16</issue>), <fpage>8028</fpage>&#x2013;<lpage>8037</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1900878116</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Won</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Roche</surname>
<given-names>K. W.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Regulation of Glutamate Receptors by Striatal-Enriched Tyrosine Phosphatase 61 (STEP61 )</article-title>. <source>J.&#x20;Physiol.</source> <volume>599</volume> (<issue>2</issue>), <fpage>443</fpage>&#x2013;<lpage>451</lpage>. <pub-id pub-id-type="doi">10.1113/JP278703</pub-id> </citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yasuda</surname>
<given-names>R. P.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Adenosine STEPs on Synaptic Function: An Editorial for &#x27;The Activity of the STriatal-Enriched Protein Tyrosine Phosphatase in Neuronal Cells Is Modulated by Adenosine A2A Receptor on&#x27; page 284</article-title>. <source>J.&#x20;Neurochem.</source> <volume>152</volume> (<issue>3</issue>), <fpage>270</fpage>&#x2013;<lpage>272</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.14901</pub-id> </citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kurup</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Carty</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Fernandez</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Nygaard</surname>
<given-names>H. B.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Genetic Reduction of Striatal-Enriched Tyrosine Phosphatase (STEP) Reverses Cognitive and Cellular Deficits in an Alzheimer&#x27;s Disease Mouse Model</article-title>. <source>Proc. Natl. Acad. Sci. U S A.</source> <volume>107</volume> (<issue>44</issue>), <fpage>19014</fpage>&#x2013;<lpage>19019</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1013543107</pub-id> </citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Venkitaramani</surname>
<given-names>D. V.</given-names>
</name>
<name>
<surname>Gladding</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kurup</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Molnar</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2008</year>). <article-title>The Tyrosine Phosphatase STEP Mediates AMPA Receptor Endocytosis after Metabotropic Glutamate Receptor Stimulation</article-title>. <source>J.&#x20;Neurosci.</source> <volume>28</volume> (<issue>42</issue>), <fpage>10561</fpage>&#x2013;<lpage>10566</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.2666-08.2008</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>
